SCHEMBL3119823

SCHEMBL3119823

CCN(C(=O)O)c1cccc(Cn2nc(-c3ccc(-c4noc(=O)[nH]4)cc3)ccc2=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAOB P27338 1/20 0.41
▸ LTB4R2 Q9NPC1 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MET P08581 6/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ HDAC1 Q13547 1/20 0.39
▸ PLA2G2A P14555 1/20 0.39
▸ CHEK1 O14757 1/20 0.38
▸ NEK2 P51955 1/20 0.38
▸ LIMK1 P53667 1/20 0.38
▸ TYRO3 Q06418 1/20 0.38
▸ CLK4 Q9HAZ1 1/20 0.38
▸ IRAK1 P51617 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3119589 0.84 MEN1 (0.50) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3119810 0.84 MEN1 (0.50) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3112440 0.84 MEN1 (0.50) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3119996 0.83 MEN1 (0.45) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3118427 0.83 MET (0.59) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3103580 0.81 MEN1 (0.48) MEN1KMT2AMAPTSMN1; SMN2MET
SCHEMBL3122723 0.80 MET (0.48) MEN1KMT2AMETPDE4APDE4B
SCHEMBL3109927 0.79 HDAC1 (0.45) MEN1KMT2AMETPDE4APDE4B
SCHEMBL3108392 0.79 MET (0.47) MEN1KMT2AMETPDE4APDE4B
SCHEMBL3108456 0.79 MEN1 (0.48) MEN1KMT2AMAPTSMN1; SMN2MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367668-B2 Pyridazinone derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-02-05 — — US disclosed
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2010-07-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179148-A1 PYRIDAZINONE DERIVATIVES MET, ERBB2, RET MEN1 121/4885KMT2A 1002/4885MAOB 1271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback